The 88.1% market-implied probability of no Merck-Moderna merger or acquisition announced in 2026 reflects the absence of any disclosed discussions, regulatory filings, or strategic signals from either company. Their long-standing 50/50 collaboration on intismeran autogene (V940) with Keytruda produced positive Phase 3 INTerpath-001 melanoma data in August, driving sharp share-price gains and validating the existing profit-sharing model without prompting consolidation. Recent analyst commentary has highlighted a potential strategic fit given Keytruda’s upcoming U.S. competition in 2028 and Moderna’s manufacturing scale-up needs, yet corporate disclosures and capital allocation priorities remain centered on advancing additional solid-tumor trials and regulatory submissions rather than M&A. With limited time left in 2026 and no evident catalysts on the horizon, trader sentiment aligns with historical precedent for such deals requiring extended negotiations.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · ОновленоMerck & Moderna merger/acquisition announced in 2026?
Merck & Moderna merger/acquisition announced in 2026?
14% шанс
НОВЕ
НОВЕ
Dec 31, 2026
14% шанс
НОВЕ
НОВЕ
Dec 31, 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.The 88.1% market-implied probability of no Merck-Moderna merger or acquisition announced in 2026 reflects the absence of any disclosed discussions, regulatory filings, or strategic signals from either company. Their long-standing 50/50 collaboration on intismeran autogene (V940) with Keytruda produced positive Phase 3 INTerpath-001 melanoma data in August, driving sharp share-price gains and validating the existing profit-sharing model without prompting consolidation. Recent analyst commentary has highlighted a potential strategic fit given Keytruda’s upcoming U.S. competition in 2028 and Moderna’s manufacturing scale-up needs, yet corporate disclosures and capital allocation priorities remain centered on advancing additional solid-tumor trials and regulatory submissions rather than M&A. With limited time left in 2026 and no evident catalysts on the horizon, trader sentiment aligns with historical precedent for such deals requiring extended negotiations.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Ринок відкрито: Aug 19, 2026, 3:58 PM ET
Обсяг
$458Дата завершення
Jan 1, 2027Ринок відкрито
Aug 19, 2026, 3:58 PM ETВирішувач
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.The 88.1% market-implied probability of no Merck-Moderna merger or acquisition announced in 2026 reflects the absence of any disclosed discussions, regulatory filings, or strategic signals from either company. Their long-standing 50/50 collaboration on intismeran autogene (V940) with Keytruda produced positive Phase 3 INTerpath-001 melanoma data in August, driving sharp share-price gains and validating the existing profit-sharing model without prompting consolidation. Recent analyst commentary has highlighted a potential strategic fit given Keytruda’s upcoming U.S. competition in 2028 and Moderna’s manufacturing scale-up needs, yet corporate disclosures and capital allocation priorities remain centered on advancing additional solid-tumor trials and regulatory submissions rather than M&A. With limited time left in 2026 and no evident catalysts on the horizon, trader sentiment aligns with historical precedent for such deals requiring extended negotiations.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Обсяг
$458Дата завершення
Jan 1, 2027Ринок відкрито
Aug 19, 2026, 3:58 PM ETВирішувач
0x65070BE91...The 88.1% market-implied probability of no Merck-Moderna merger or acquisition announced in 2026 reflects the absence of any disclosed discussions, regulatory filings, or strategic signals from either company. Their long-standing 50/50 collaboration on intismeran autogene (V940) with Keytruda produced positive Phase 3 INTerpath-001 melanoma data in August, driving sharp share-price gains and validating the existing profit-sharing model without prompting consolidation. Recent analyst commentary has highlighted a potential strategic fit given Keytruda’s upcoming U.S. competition in 2028 and Moderna’s manufacturing scale-up needs, yet corporate disclosures and capital allocation priorities remain centered on advancing additional solid-tumor trials and regulatory submissions rather than M&A. With limited time left in 2026 and no evident catalysts on the horizon, trader sentiment aligns with historical precedent for such deals requiring extended negotiations.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання